Budget Impact and Incremental Survival Benefit of Eribulin Mesylate as a Treatment for Metastatic Breast Cancer in Brazil
Value Health
.
2014 Nov;17(7):A623.
doi: 10.1016/j.jval.2014.08.2211.
Epub 2014 Oct 26.
Authors
U Majethia
1
,
G Tremblay
2
,
L Borges
3
,
T Jones
1
,
A Forsythe
2
,
D Pomerantz
4
,
O A C Clark
5
Affiliations
1
Eisai, Woodcliff Lake, NJ, USA.
2
Eisai Inc, Woodcliff Lake, NJ, USA.
3
Evidências, Campinas, Brazil.
4
Kantar Health, Princeton, NJ, USA.
5
Evidencias, Campinas, Brazil.
PMID:
27202196
DOI:
10.1016/j.jval.2014.08.2211
No abstract available